世界のインスリングラルギン市場産業概要と2031年までの予測 - 市場分析と市場シェア

世界のインスリン グラルギン市場 - 業界概要

世界のインスリン グラルギン市場は、糖尿病、特に糖尿病症例全体の約 90 ～ 95% を占める 2 型糖尿病の発症率の上昇に支えられ、大幅な成長を遂げています。長時間作用型インスリン アナログであるインスリン グラルギンは、1 日 1 回の注射で 24 時間にわたって安定した基礎インスリン レベルを提供するように設計されており、糖尿病管理を簡素化し、患者の服薬遵守を強化します。この利便性により、患者の服薬遵守が向上するだけでなく、全体的な治療結果も向上するため、インスリン グラルギンは医療従事者と患者の双方に好まれる選択肢となっています。

Data Bridge Market Research の市場レポートでは、最近の新しい開発、市場シェア、セグメンテーションと地域分析に基づく市場動向、市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的な市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。市場に関する詳細情報を入手するには、Data Bridge Market Research の専門アナリスト チームにお問い合わせください。当社のチームは、情報に基づいた市場決定を行い、ビジネスの成長を達成できるようお手伝いします。

世界のインスリングラルギン市場 – 市場分析と市場規模

インスリン グラルギンには、他のインスリン療法に伴う一般的な重篤な副作用である低血糖のリスクを軽減する能力があるため、市場の拡大がさらに促進されています。このような予測可能な薬物動態プロファイルにより、インスリン グラルギンは糖尿病治療の礎となり、広く採用され、市場の成長を牽引しています。その結果、Databridge Market Research は市場を包括的に分析し、世界のインスリン グラルギン市場が 6.70% の CAGR で成長していることを明らかにしました。当社の詳細な分析では、市場は 2023 年に 65 億 6,000 万米ドルと評価され、2031 年までに 110 億 3,000 万米ドルまで成長すると予測されています。包括的な調査と分析を通じて綿密に作成された当社のレポートは、市場に関する驚くべきデータを明らかにする傑出した論文です。

世界のインスリン グラルギン市場 – 市場動向

Global Insulin Glargine Market Growth Drivers

Rising cases of Type-2 diabetes

According to the IDF Diabetes Atlas, 537 million adults (1 in 10) were living with diabetes in 2021, with this number expected to rise to 643 million by 2030 and 783 million by 2045. The anticipated surge in diabetes cases underscores the critical need for advanced insulin therapies, positioning Insulin Glargine as a key driver in the market's expansion.

Rising geriatric population

According to the World Health Organization (WHO), by 2050, the global population of people aged 60 years and older is expected to double, reaching 2.1 billion. As the elderly population grows, so does the prevalence of age-related conditions, including type 2 diabetes, which is more common among older adults. The need for effective diabetes management solutions in this age group is critical, and Insulin Glargine, with its stable, long-acting glucose control and once-daily dosing, is particularly well-suited for older patients. Growing demand for tailored insulin therapies among the aging population is propelling the Global Insulin Glargine market growth.

Global Insulin Glargine Market Growth Opportunities

Increasing Government Initiatives and Healthcare Policies

Emerging markets such as India, Brazil, and China have witnessed a significant investment in healthcare infrastructure. For Instance, India’s government launched the Ayushman Bharat scheme, aimed at providing healthcare services to over 500 million people, particularly in rural and underserved areas. This scheme includes the establishment of thousands of Health and Wellness Centers across the country, many of which are equipped to manage chronic diseases like diabetes consequently, fostering the Global Insulin Glargine Market Growth.

Development of Biosimilars

The development and approval of biosimilar versions of insulin glargine represents a substantial growth opportunity for the Global Insulin Glargine Market, particularly in price-sensitive regions. Eli Lilly and Boehringer Ingelheim developed Basaglar, a biosimilar to insulin glargine. Basaglar was among the first insulin glargine biosimilars approved by both the FDA in the United States and the European Medicines Agency (EMA) in Europe. Its approval represented a crucial step in making insulin glargine more affordable and accessible.

Global Insulin Glargine Market Growth Challenges

Complex Manufacturing Process

Insulin glargine, like other biologics, necessitates a complicated and sophisticated production procedure. Production requires advanced biotechnological processes, tight quality control, and adherence to regulatory norms, all of which contribute to high production costs. These expenses may limit the affordability of insulin glargine, particularly in low-income areas, limiting Global Insulin Glargine Market expansion.

Supply Chain Disruptions

During the 2022 global semiconductor shortage insulin manufacturers faced delays in production and distribution. The shortage of key components used in the production of insulin delivery devices, like insulin pumps and pens, led to reduced availability of insulin glargine for patients. Geopolitical tensions, such as the trade restrictions imposed during the U.S.-China trade war, further complicated logistics and import-export processes, exacerbating shortages and increasing costs for insulin glargine. Such disruptions not only exacerbated shortages but also increased costs, underscoring how vulnerabilities in the supply chain can impede Global Insulin Glargine Market growth.

Global Insulin Glargine Market Restraints

Regulatory and Reimbursement Challenges

In the Global Insulin Glargine (PPD) market, approval delays are a major regulatory constraint that are frequently caused by the drawn-out and intricate procedures mandated by organizations such as the FDA and EMA. For instance, it took several years for the first drug licensed particularly for PPD, brexanolone (Zulresso), to get approval. The entire process from first proposal to approval took almost ten years, despite the breakthrough status, showing how regulatory obstacles can cause delays in the availability of novel medications. Such Delays hamper the introduction of novel medicines, which can hinder the Global Insulin Glargine Market expansion.

Global Insulin Glargine Market Scope and Trends

• The combination of insulin icodec and semaglutide has shown promising results in managing type 2 diabetes by effectively reducing HbA1c levels and body weight. Insulin icodec, a novel long-acting insulin with a once-weekly dosing regimen, provides sustained glycemic control, while semaglutide, a GLP-1 receptor agonist, enhances glucose-dependent insulin secretion and suppresses appetite.
• Sanofi launches an anti-diabetic medication in India. Soliqua is a once-daily injectable combination medicine that includes insulin glargine 100 Units/ml, a long-acting basal insulin, and lixisenatide, a GLP-1 receptor agonist.

Global Insulin Glargine Market Regional Analysis – Market Trends

Key Insights

• In North America, The U.S. and Canada have a well-established market for insulin glargine, driven by high diabetes prevalence and advanced healthcare systems. The U.S. market is particularly strong due to extensive insurance coverage and high patient demand.
• The European market shows strong performance, particularly in Western Europe, with countries like Germany and France leading in insulin glargine adoption. The region’s well-established healthcare systems and favorable reimbursement frameworks facilitate widespread access. Additionally, initiatives to improve diabetes care in Eastern and Southern Europe are expected to boost market growth.
• The Asia Pacific region presents tremendous growth opportunities, with China and India at the forefront. In China, expanding healthcare coverage and increasing public health initiatives are driving market expansion, while India’s burgeoning healthcare sector and rising diabetes awareness offer significant growth potential. The increasing focus on diabetes management in countries like Japan and South Korea also contributes to a positive market outlook.
• Optimistic growth prospects are evident in the Middle East and parts of Africa. Countries like Saudi Arabia and South Africa are expanding their healthcare infrastructure and diabetes management programs, creating a favorable environment for insulin glargine. Continued investments in healthcare and increasing public health initiatives are expected to accelerate market development in these regions.

Global Insulin Glargine Market Leading Players

• Biocon (India)
• Sanofi-Aventis (France)
• Novo Nordisk A/S (Denmark)
• Lilly (U.S.)
• LGM Pharma (U.S.)
• Trumac Healthcare (India)
• Gan & Lee Pharmaceuticals (China)
• ADOCIA (France)
• Lupin Ltd (India)
• WOCKHARDT (India)
• Cipla Inc. (India)
• Pfizer Inc. (U.S.)
• Biogenomics Limited (India)
• Loka Biosciences (India)
• Amigoz Lifesciences (India)
• Endocrine Technologies, Inc. (U.S.)
• Alfa Chemical Corp. (India)
• Accurate Chemical & Scientific Corporation (U.S.)
• Spectrum Chemical Mfg. Corp. (India)
• Sekisui Diagnostics LLC (U.S.)

 Global Insulin Glargine Market Recent Developments

• In January 2024, A study conducted by the Doctors of India Diabetes Research Foundation and Dr. A. Ramachandran's Diabetes Hospitals discovered that two doses of insulin (basal insulin analog), while higher in dose, are marginally better than a single shot (premixed insulin) in decreasing HbA1c (glycated haemoglobin). The study's findings highlighted the need of initiating insulin therapy on time.
• In June, 2024 Geropharm, a Russian company, has started delivering insulin products to Morocco. The first shipment of 97 thousand syringe pens containing long-acting insulin glargine has already left for the country. The deal with Morocco for the provision of insulin was extended until 2026.
• 2023年3月、イーライリリー・アンド・カンパニーは、最も広く処方されているインスリンの価格を70%引き下げるとともに、患者の自己負担額を1か月あたり35ドル以下に制限するインスリンバリュープログラムの拡大を発表しました。リリーは、リリーのインスリンをより入手しやすくし、複雑な医療制度を理解するのに苦労して安価なインスリンを入手できない可能性のあるアメリカ人を支援するために、これらの措置を講じています。

SKU-59051